Astrazeneca Plc $AZN Shares Sold by Oxbow Advisors LLC

Oxbow Advisors LLC reduced its stake in Astrazeneca Plc (NYSE:AZN) by 48.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,552 shares of the company’s stock after selling 37,736 shares during the period. Oxbow Advisors LLC’s holdings in Astrazeneca were worth $7,998,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Triumph Capital Management purchased a new stake in shares of Astrazeneca during the 3rd quarter worth approximately $25,000. MV Capital Management Inc. acquired a new position in shares of Astrazeneca in the 4th quarter valued at $26,000. Bangor Savings Bank grew its position in shares of Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after buying an additional 154 shares during the last quarter. Eagle Bay Advisors LLC purchased a new position in shares of Astrazeneca in the 4th quarter valued at $30,000. Finally, YANKCOM Partnership acquired a new stake in Astrazeneca during the 4th quarter worth $31,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Stock Performance

Shares of Astrazeneca stock opened at $194.96 on Friday. The firm’s fifty day simple moving average is $183.96 and its 200-day simple moving average is $187.95. The stock has a market capitalization of $302.36 billion, a price-to-earnings ratio of 29.27, a PEG ratio of 1.58 and a beta of 0.24. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The firm had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. As a group, equities analysts forecast that Astrazeneca Plc will post 10.28 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on AZN shares. Weiss Ratings cut shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 18th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a report on Tuesday. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Tuesday. Fourteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.